Immunome’s (IMNM) Outperform Rating Reaffirmed at Wedbush

Wedbush restated their outperform rating on shares of Immunome (NASDAQ:IMNM) in a research report report published on Monday,RTT News reports. Wedbush currently has a $33.00 price target on the stock.

Several other research firms have also issued reports on IMNM. Stephens assumed coverage on shares of Immunome in a report on Friday, November 8th. They issued an “overweight” rating and a $30.00 target price for the company. Piper Sandler decreased their price objective on shares of Immunome from $23.00 to $21.00 and set an “overweight” rating on the stock in a research report on Thursday, November 14th. Seven research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Immunome has a consensus rating of “Buy” and a consensus price target of $28.83.

Immunome Stock Performance

NASDAQ:IMNM opened at $10.04 on Monday. The stock has a 50-day simple moving average of $11.72 and a two-hundred day simple moving average of $12.98. The firm has a market capitalization of $626.67 million, a PE ratio of -1.24 and a beta of 1.90. Immunome has a 52-week low of $8.97 and a 52-week high of $30.96.

Insider Transactions at Immunome

In other news, CEO Clay B. Siegall purchased 66,057 shares of the company’s stock in a transaction that occurred on Thursday, November 21st. The stock was bought at an average cost of $9.54 per share, with a total value of $630,183.78. Following the completion of the purchase, the chief executive officer now owns 485,693 shares in the company, valued at approximately $4,633,511.22. This represents a 15.74 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, insider Robert Lechleider purchased 15,805 shares of the business’s stock in a transaction on Thursday, November 21st. The shares were purchased at an average price of $9.48 per share, with a total value of $149,831.40. Following the acquisition, the insider now directly owns 15,805 shares in the company, valued at $149,831.40. This represents a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 102,862 shares of company stock valued at $978,045. 8.60% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Immunome

Hedge funds have recently bought and sold shares of the business. Bank of New York Mellon Corp bought a new stake in shares of Immunome in the 2nd quarter worth about $1,816,000. Rhumbline Advisers bought a new stake in Immunome during the second quarter worth approximately $813,000. Victory Capital Management Inc. raised its position in Immunome by 39.0% during the second quarter. Victory Capital Management Inc. now owns 493,288 shares of the company’s stock valued at $5,969,000 after purchasing an additional 138,526 shares during the period. Arizona State Retirement System lifted its stake in shares of Immunome by 9.2% in the 2nd quarter. Arizona State Retirement System now owns 10,862 shares of the company’s stock valued at $131,000 after purchasing an additional 918 shares during the last quarter. Finally, Quest Partners LLC purchased a new position in shares of Immunome in the 2nd quarter worth approximately $81,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.